1
Brunner, Andrew M., Esteve, Jordi, Porkka, Kimmo, Knapper, Steve, Traer, Elie, Scholl, Sebastian, Garcia-Manero, Guillermo, Vey, Norbert, Wermke, Martin, Janssen, Jeroen J. W. M., Narayan, Rupa, Fleming, Shaun, Loo, Sun, Tovar, Natalia, Kontro, Mika, Ottmann, Oliver G., Naidu, Purushotham, Sun, Haiying, Han, May, White, Roisin, Zhang, Na, Mohammed, Anisa, Sabatos-Peyton, Catherine A., Steensma, David P., Rinne, Mikael L., Borate, Uma M., Wei, Andrew H.
Veröffentlicht in: Brunner , A M , Esteve , J , Porkka , K , Knapper , S , Traer , E , Scholl , S , Garcia-Manero , G , Vey , N , Wermke , M , Janssen , J J W M , Narayan , R , Fleming , S , Loo , S , Tovar , N , Kontro , M , Ottmann , O G , Naidu , P , Sun , H , Han , M , White , R , Zhang , N , Mohammed , A , Sabatos-Peyton , C A , Steensma , D P , Rinne , M L , Borate , U M & Wei , A H 2023 , ' Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes ' , American Journal of Hematology . https://doi.org/10.1002/ajh.27161;
2023
Veröffentlicht in: Brunner , A M , Esteve , J , Porkka , K , Knapper , S , Traer , E , Scholl , S , Garcia-Manero , G , Vey , N , Wermke , M , Janssen , J J W M , Narayan , R , Fleming , S , Loo , S , Tovar , N , Kontro , M , Ottmann , O G , Naidu , P , Sun , H , Han , M , White , R , Zhang , N , Mohammed , A , Sabatos-Peyton , C A , Steensma , D P , Rinne , M L , Borate , U M & Wei , A H 2023 , ' Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes ' , American Journal of Hematology . https://doi.org/10.1002/ajh.27161;
2023